Literature DB >> 14652790

Imaging neuronal and axonal degeneration in multiple sclerosis.

N De Stefano1, L Guidi, M L Stromillo, M L Bartolozzi, A Federico.   

Abstract

Neuronal and axonal damage has become an important issue in multiple sclerosis. This has been emphasised by recent magnetic resonance imaging (MRI) studies that have shown evidence of axonal damage in both lesional and non-lesional white matter and in grey matter. In this respect, proton MR spectroscopy (by monitoring levels of Nacetylaspartate, a putative marker of axonal integrity) and computed measurements of cerebral volumes have been particularly illuminating. Recent studies using these MRI measures have demonstrated that cerebral neuro-axonal damage begins and contributes to disability from the earliest stages of the disease. This implies that the apparently primary role of neuronal pathology in the pathogenesis of the disease should be given due importance and argues for the early treatment of multiple sclerosis with agents directed not only against inflammation, but also towards neuronal protection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652790     DOI: 10.1007/s10072-003-0175-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  11 in total

Review 1.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 2.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

3.  (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas.

Authors:  Eunkyung Park; Jean-Dominique Gallezot; Aracely Delgadillo; Shuang Liu; Beata Planeta; Shu-Fei Lin; Kevin C O'Connor; Keunpoong Lim; Jae-Yun Lee; Anne Chastre; Ming-Kai Chen; Nicholas Seneca; David Leppert; Yiyun Huang; Richard E Carson; Daniel Pelletier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-02       Impact factor: 9.236

Review 4.  Autoimmune modulation of astrocyte-mediated homeostasis.

Authors:  Thomas Korn; Mahendra Rao; Tim Magnus
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 5.  Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.

Authors:  Chaitanya R Joshi; Vinod Labhasetwar; Anuja Ghorpade
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-03       Impact factor: 4.147

Review 6.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

7.  MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study.

Authors:  J Bellmann-Strobl; H Stiepani; J Wuerfel; G Bohner; F Paul; C Warmuth; O Aktas; K P Wandinger; F Zipp; R Klingebiel
Journal:  Eur Radiol       Date:  2009-03-24       Impact factor: 5.315

Review 8.  Animal modeling of lower urinary tract dysfunction associated with multiple sclerosis: Part I: Justification of the mouse model for MS research.

Authors:  Ramalakshmi Ramasamy; Phillip P Smith
Journal:  Neurourol Urodyn       Date:  2021-03-14       Impact factor: 2.696

9.  Correlation between white matter damage and gray matter lesions in multiple sclerosis patients.

Authors:  Xue-Mei Han; Hong-Ji Tian; Zheng Han; Ce Zhang; Ying Liu; Jie-Bing Gu; Rohit Bakshi; Xia Cao
Journal:  Neural Regen Res       Date:  2017-05       Impact factor: 5.135

10.  N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry.

Authors:  Bas Jasperse; Cornelis Jakobs; M Judith Eikelenboom; Christine D Dijkstra; Bernard M J Uitdehaag; Frederik Barkhof; Chris H Polman; Charlotte E Teunissen
Journal:  J Neurol       Date:  2007-04-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.